Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

ConclusionsRadium-223 is effective and well tolerated in Japanese patients with CRPC and bone metastases. Results were comparable with the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.Clinical trial registrationClinicalTrials.gov NCT01929655.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research